Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theralase TechnologiesTLTFF -1.37%45 EV-to-EBITDA is -21.50 as of Jul. 19, 2026. GuruFocus rates TLTFF with a GF Score™ of 45/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Theralase Technologies ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Theralase Technologies's enterprise value is $52.70 Mil.
Theralase Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.45 Mil. Therefore, Theralase Technologies's EV-to-EBITDA for today is -21.50.
The historical rank and industry rank for Theralase Technologies's EV-to-EBITDA or its related term are showing as below:
TLTFF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.52 Med: -10.36 Max: -1.55
Current: -22.2
During the past 13 years, the highest EV-to-EBITDA of Theralase Technologies was -1.55. The lowest was -30.52. And the median was -10.36.
TLTFF's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.155
vs TLTFF: -22.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Theralase Technologies's PE Ratio (TTM) for today is calculated as:
Theralase Technologies's share price for today is $0.18.
Theralase Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's EV-to-EBITDA falls into.
Theralase Technologies's current Enterprise Value is $52.70 Mil.
Theralase Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a EV-to-EBITDA of -21.50 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Theralase Technologies. According to the industry distribution chart, Theralase Technologies ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is Theralase Technologies' EV-to-EBITDA too high?
Theralase Technologies' current EV-to-EBITDA is -21.50. Based on the distribution chart, Theralase Technologies ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theralase Technologies has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #999999 out of 510 companies for EV-to-EBITDA. This places Theralase Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 14.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.16, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Theralase Technologies. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current EV-to-EBITDA is -21.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 38.5% above its estimated fair value. The current EV-to-EBITDA is -21.50. Theralase Technologies' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current EV-to-EBITDA is -21.50 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.18 is trading 38.5% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Significantly Overvalued.
Key valuation signals for TLTFF:
EV-to-EBITDA: -21.50
GF Value™: $0.13 vs. price of $0.18 (38.5% above fair value)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
45GF Score
Get the complete analysis for TLTFF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
